41 results about "Mitiromycin" patented technology

The invention belongs to the field of biological control, and particularly discloses a biocontrol strain streptomyces mitomycin and application thereof.The strain is streptomyces mitomycin LZ-734 and is preserved in the China General Microbiological Culture Collection Center on October 9th, 2024, the preservation number is CCTCC NO: 32156, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. According to the present invention, the fermentation crude extract of Streptomyces mumenini LZ-734 has good inhibition effects on Magnaporthe oryzae and rhizoctonia solani, the inhibition rate on the Magnaporthe oryzae reaches 99.06%, and the inhibition rate on the rhizoctonia solani is 66.61%, such that the Streptomyces mumenini LZ-734 can be used for prevention and control of rice blast and rice sheath blight disease, and has good development and application prospects.

A liposome composition comprising a lipophilic prodrug of mitomycin C having an improved pharmacokinetic profile is described. A method for preparing the composition with a solvent system comprised of ethanol and tertiary butanol mixed at an adequate ratio is also described. In an embodiment, the liposome composition is a population of lipid nanoparticles and a pharmaceutically acceptable vehicle, wherein the population of lipid nanoparticles is comprised of a first fraction of spherical liposomes and a second fraction of rod-shaped lipid nanoparticles, where the second fraction is less than about 15% of the population of lipid nanoparticles.

The medicine preparation device comprises a container, a medicine containing piece and a cover plate, an opening is formed in the top of the container, and an injection opening for an injector to be inserted in is formed in the side wall of the container; the medicine loading piece is movably arranged at the opening, is provided with a sinking groove formed in the container and is used for placing freeze-dried powder; the cover plate is movably connected to the container and used for opening or closing the opening; when the medicine loading piece moves, the groove wall of the sinking groove can open or close the injection opening. According to the technical scheme, the medicine containing part is movably installed at the opening of the container, the injection opening of the container is opened and communicated with the interior of the container, the injector can inject a solvent to dissolve freeze-dried powder in the medicine containing part, the medicine containing part continues to move to close the injection opening, and liquid medicine which is not completely dissolved is prevented from flowing back to the injector. According to the device, the injection port can be closed during configuration, and the injection port is opened after dissolution is completed, so that liquid medicine is effectively prevented from flowing back to the injector, and the medicine effect of the injector can be guaranteed.

The present invention belongs to the field of insect cell culture technology and discloses a method for preparing an Sf9 cell feeder layer. The method mainly comprises two steps: step S1 is subculture of Sf9 cells, in which Sf9 cells are cultured in a suitable culture medium to a suitable cell confluence; step S2 is mitomycin C treatment of the Sf9 cells, in which a specific concentration of mitomycin C is used to treat the subcultured Sf9 cells at a specific time and temperature to inhibit their cell division ability, followed by washing to remove mitomycin C and replacing with fresh culture medium. The feeder layer cells obtained by the present invention can effectively inhibit their own proliferation while maintaining good cell activity and structural integrity. They can survive stably and provide necessary support for the co-culture system. They can be used for the cultivation of insect symbiotic bacteria and other difficult-to-culture insect cells. The method is simple to operate, has mild conditions, and good reproducibility. The prepared feeder layer has a stable effect, providing a powerful tool for related research fields.

In specific embodiments, provided is a material for preventing adhesion of membranes in an ophthalmic surgery for treatment of glaucoma or the like without using mitomycin-C or the like. Particularly provided is such material, which is easy to handle and has no risk of histolysis or infections. In a production method of a preferred embodiment, prepared are: aldehyde-modified dextran (first reactant) having weight-average molecular weight of 10,000-5,000,000 and introduced aldehyde group-per-anhydrous glucose unit (mol / AGU) of 0.4-0.7; and succinic anhydride-added poly-L-lysine (second reactant) having weight-average molecular weight of 1000-100,000 and having residual amino group ratio of 80-99%; then, they are mixed together so that aldehyde group-to-amino group molar ratio becomes 0.9-1.1 and are reacted in presence of water so that polymer concentration becomes 8-20%; and a hydrogel produced by the reaction, or a suspension before gelation, is freeze-dried to produce a porous sheet having a thickness of 0.1-0.8 mm.

In specific embodiments, provided is a material for preventing adhesion of membranes in an ophthalmic surgery for treatment of glaucoma or the like without using mitomycin-C or the like. Particularly provided is such material, which is easy to handle and has no risk of histolysis or infections. In a production method of a preferred embodiment, prepared are: aldehyde-modified dextran (first reactant) having weight-average molecular weight of 10,000-5,000,000 and introduced aldehyde group-per-anhydrous glucose unit (mol / AGU) of 0.4-0.7; and succinic anhydride-added poly-L-lysine (second reactant) having weight-average molecular weight of 1000-100,000 and having residual amino group ratio of 80-99%; then, they are mixed together so that aldehyde group-to-amino group molar ratio becomes 0.9-1.1 and are reacted in presence of water so that polymer concentration becomes 8-20%; and a hydrogel produced by the reaction, or a suspension before gelation, is freeze-dried to produce a porous sheet having a thickness of 0.1-0.8 mm.

The invention provides a co-culture system for increasing the yield of endometrial stem cell exosomes and a method for increasing the yield of endometrial stem cell exosomes, firstly, fibroblasts are subjected to mitomycin C pretreatment, so that the cells are stagnated in G1, S and G2 stages of a cell cycle, meanwhile, RNA and protein synthesis continues to be carried out, and the endometrial stem cell exosomes are obtained; the fibroblasts are kept in a non-proliferative but metabolic active state; then, endometrial stem cells extracted from endometrial tissues in the proliferation period and fibroblasts are indirectly co-cultured through a Transwell chamber and are separated through a semi-permeable membrane, and stem cell differentiation caused by inter-cell contact reaction and fusion of the stem cells and somatic cells is eliminated; after co-culture, taking out the endometrial stem cells, putting the endometrial stem cells into a serum-free culture medium special for exosomes for separate culture, harvesting cell supernate, and purifying the exosomes; compared with the endometrial stem cells which are independently cultured in the whole process, the co-culture system disclosed by the invention has the advantages that the amplification speed of the endometrial stem cells and the exosome yield of unit quantity of cells are remarkably improved.

A lysogenic phage community, its extraction method and application. The tangential flow technology is used to proportionally isolate bacteria and phage communities from in-situ soil, and single-bacteria communities and single-phage communities are obtained through enrichment and concentration. At the same time, mitomycin C is added to the single-bacteria community for lysogenic induction, and then the tangential flow system is used again for filtration and enrichment to obtain a high-throughput lysogenic phage community. Finally, we obtain single-bacteria communities, bacteria-phage mixed communities, and bacteria-lysogenic phage mixed communities. The phage transplantation technology can promote the participation of indigenous microorganisms in the process of promoting plant growth and development. The transplanted lysogenic phages can participate in the synthesis and metabolism of host plant hormones by optimizing the microbial network structure and injecting auxiliary metabolic genes. This method provides a long-term and environmentally friendly microbial synergistic growth promotion technology for the development of green agriculture in China.

The invention relates to the technical field of medicines, in particular to an enantiomer-atesane type diterpenoid compound as well as a preparation method and an application of the enantiomer-atesane type diterpenoid compound. The enantiomer-atesane diterpenoid compound disclosed by the invention is derived from plants, has anti-tumor activity, has cytotoxicity to human leukemia cells, human liver cancer cells and human cervical cancer cells, and is relatively good in inhibitory activity. Wherein the compound 3 has the best effect, the IC50 values of the compound 3 to three human tumor cells are 7.5 + / -1.2 micromole per liter, 9.8 + / -1.0 micromole per liter and 10.1 + / -0.9 micromole per liter respectively, and the activity of the compound 3 is equivalent to that of a positive control drug mitomycin. Particularly, the compound 3 also has good cytotoxicity to drug-resistant liver cancer cells (Huh7-LR cells), and the IC50 value of the compound 3 is 9.6 + / -1.1 micromole per liter. The compound 3 shows huge potential as a lead compound by virtue of the novel chemical structure and potent cytotoxicity shown in various cell lines.

The invention provides a method for purifying mitomycin C. The method comprises the following steps: step 1, adding a surfactant or / and guanidine hydrochloride into fermentation liquor, and carrying out solid-liquid separation; 2, separating through a chromatographic column to obtain a solution containing mitomycin C; and step 3, obtaining a mitomycin C solid from the mitomycin C solution. According to the method provided by the invention, high-purity mitomycin C can be obtained, the yield is high, and the method is suitable for large-scale industrial production.

A liposome composition comprising a lipophilic prodrug of mitomycin C having an improved pharmacokinetic profile is described. A method for preparing the composition with a solvent system comprised of ethanol and tertiary butanol mixed at an adequate ratio is also described. In an embodiment, the liposome composition is a population of lipid nanoparticles and a pharmaceutically acceptable vehicle, wherein the population of lipid nanoparticles is comprised of a first fraction of spherical liposomes and a second fraction of rod-shaped lipid nanoparticles, where the second fraction is less than about 15% of the population of lipid nanoparticles.

The present invention concerns antibody-conjugate having general structure (2):wherein AB is an antibody capable of targeting Trop-2-expressing tumours and D is selected from the group consisting of taxanes, anthracyclines, camptothecins, epothilones, mytomycins, combretastatins, vinca alkaloids, maytansinoids, enediynes such as calicheamicins, duocarmycins, tubulysins, amatoxins, bleomycins, dolastatins and auristatins, pyrrolobenzodiazepine dimers, indolinobenzodiazepine dimers, radioisotopes, therapeutic proteins and peptides (or fragments thereof), kinase inhibitors, MEK inhibitors, KSP inhibitors, and analogues or prodrugs thereof. These antibody-conjugates exhibit an improved therapeutic index. The invention further concerns a process for preparing the antibody-conjugate according to the invention, a method for targeting Trop-2-expressing cells, medical uses of the antibody-conjugates according to the invention.

The invention provides a method for induced directional differentiation of iPS pluripotent stem cells into neural stem cells and application, and belongs to the technical field of stem cells. Comprising the following steps: S1, preparation of a culture medium: adding silk fibroin peptide and mitomycin C into a DMEM culture medium to prepare the culture medium; s2, subculture: inoculating the human iPS cells into a culture medium, culturing, digesting, blowing down colonies, adding into a new culture medium again, carrying out differential attachment, and collecting suspension cells; s3, induction: re-dispersing the suspension cells in the culture medium, adding an inducer, and performing induction culture to obtain differentiated neural stem cells. The method is simple, wide in raw material source and mild in condition, can induce directional differentiation of ips pluripotent stem cells into neural stem cells, can realize induction culture of neural stem cells, and has a wide application prospect.

The invention belongs to the field of molecular biology, and particularly relates to a construction method and application of phosphorylation mutation sites of phosphoglucomutase. The mutation site is obtained by mutating threonine at the 144th site of escherichia coli wild-type phosphoglucomutase into aspartic acid, the sensitivity of an escherichia coli mutant strain with the mutation site to nalidixic acid, mitomycin C and tetracycline is remarkably improved, and the mutation site can be used for improving the sensitivity of bacteria to drugs.

A method of reducing risk of bladder tumor recurrence, progression or death, or a method of increasing probability of disease-free survival at 15 months post-treatment, or a method of increasing probability of maintaining an achieved complete response for at least 15 months post-treatment comprises administering to a patient in need thereof a thermally gelling pharmaceutical composition once weekly for six weeks, the patient having low-grade intermediate-risk non-muscle invasive bladder cancer, and the thermally gelling pharmaceutical composition comprising a reverse thermal gelation agent, a polymer, and mitomycin. The risk is reduced or the probability is increased in comparison to the risk or probability expected if the patient were instead to receive TURBT monotherapy as treatment.

The invention discloses an application of a global stress response element DdaA in Murraziaceae. The NCBI protein sequence of the DdaA is WP000117148.1, the DdaA is used as a target site of drugs or stress and is used for preventing and treating conditional pathogen environmental microorganism moraliaceae bacteria, and the moraliaceae bacteria include but are not limited to acinetobacter baumannii. By disturbing the DdaA regulatory network, the stability of the bacterial genome of the Murraziaceae is reduced. By disturbing the DdaA regulatory network, the sensitivity of the Murraziaceae bacteria to bacteriophage infection is improved. The DdaA pathway targeted drug is used for preventing and treating by adjusting the response of moraxaceae bacteria to environmental stress. The DdaA pathway targeted drug is combined with phage therapy for prevention and treatment. Environmental stress includes and is not limited to ultraviolet irradiation and mitomycin treatment. And the drug target is a network regulated and controlled by DdaA. The medicine comprises a DNA (Deoxyribose Nucleic Acid) fragment or plasmid containing a multi-repeat DdaA binding sequence 'CGWCANNNNNTGWCG'. The composition is suitable for preventing and treating multi-drug-resistant acinetobacter baumannii And combined use can be realized, and a superposition effect is generated.

The invention discloses a mitomycin C drug sensitive marker, a detection reagent and application of the mitomycin C drug sensitive marker, the mitomycin C drug sensitive marker is a mitomycin C drug-resistant marker or / and a mitomycin C sensitive marker, and the mitomycin C drug-resistant marker is one or more of PRODH, ANKRD35, ADAMTSL5, PTPRQ, NOXA1, PRAC1, CRYM, NFIB, SYK or DGAT2; and the mitomycin C sensitive marker is one or more of GABRP (gamma-aminobutyric acid binding protein), PABPC1L (poly (p-aminobutyric acid binding protein 1L) or PODXL2 (peroxidase The mitomycin C drug sensitive marker can be used for predicting the drug effect of mitomycin C. According to the present invention, the expression of the related molecules is detected by sequencing the transcriptome of the tissue of the urothelium carcinoma patient, or by using the PC R, the gene chip, the tissue chip, the NanoString technology, the immunohistochemistry and the ELISA method, such that the clue can be provided for the medication of the mitomycin C and the precise treatment of the bladder cancer.

This invention relates to the use of small molecule compounds that allosterically inhibit ALC1 (CHD1L), particularly two classes of ALC1 (CHD1L) allosteric inhibitors of formulas (I) and (II). When combined with inhibitors of several classes of cancer drugs, namely topoisomerase I, topoisomerase II, ATM, ATR, Wee1, BRD, and MEK, or when combined with mitomycin C, paclitaxel, ionizing radiation, or antibody-drug conjugates having tumor-specific antibodies conjugated to TOP1 inhibitors, the small molecule compounds and the allosteric inhibitors exhibit enhancing, preferably additive, effects in the treatment of proliferative diseases. Furthermore, this invention relates to the ALC1 inhibitor of formula (II), which, when combined with PARP inhibitors (poly(ADP-ribose)-polymerase inhibitors (PARPi)), exhibit synergistic effects in the treatment of pancreatic cancer or fallopian tube cancer. By synergizing with the functions of the aforementioned cancer drugs, the ALC1 inhibitors, particularly those of formulas (I) and (II) that enhance the cancer cell killing properties of the aforementioned cancer drugs, are particularly capable of achieving treatments in which any of the aforementioned inhibitors have already been used as part of standard care.

The invention belongs to the field of molecular biology, and particularly relates to a construction method and application of a phosphoenolpyruvate synthase T419D mutation site. The mutation site is obtained by mutating threonine at the 419th site of phosphoenolpyruvate synthase of an escherichia coli wild type into aspartic acid, the sensitivity of an escherichia coli mutant strain with the mutation site to nalidixic acid, mitomycin C and polymyxin sulfate B is remarkably improved, and the mutation site can be used for improving the sensitivity of bacteria to drugs.

1. The name of the design product: liquid guide box (mitomycin). 2. The use of the design product: medical equipment, used for cotton piece to soak appropriate amount of liquid. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 1.

The invention discloses a ZnPc-SFeCO compound as well as a preparation method and application thereof, and discloses a general drug design method taking [2Fe-2S] (CO) 6 as an active center, a drug design strategy based on an interference lysosome arginine-SLC38A9-mTORC1-CCDK2 / 4 / 6 path is established, ZnPc-SFeCO is taken as an example, the ZnPc-SFeCO efficiently catalyzes decomposition of arginine in lysosome so as to inhibit activation of SLC38A9, and the application of the ZnPc-SFeCO compound is promoted. According to the present invention, with the application of the CDK2 / 4 / 6, the collection and the activation of the mTORC1 can be accurately blocked, the CDK2 / 4 / 6 activation retardation cell cycle progress can be inhibited, and the treatment effect superior to the clinical first-line anticancer drug mitomycin (MMC) can be obtained in the in-vivo in-situ non-muscular invasive bladder cancer (NIMBC) model and the tumor recurrence prevention and lifetime prolonging experiment.

The invention relates to the technical field of nano materials, in particular to catechol derivative ligands, gold nanoparticles modified by the catechol derivative ligands and application of the catechol derivative ligands. The catechol derivative modified gold nanoparticles provided by the invention can be used as a biological reducing agent, specifically, the specific value of GSH / GSSG in tumor cells is increased, the specific value of NADPH / NADP + is increased, the content of extracellular H2O2 is reduced, the content of GPx is increased, the content of MDA is reduced, and a reductive stress state is formed, so that the catechol derivative modified gold nanoparticles can be used as the biological reducing agent. In a reductive stress state, not only can the proliferation rate of tumor cells be inhibited, but also the mitomycin C can be activated, and the treatment effect of the mitomycin C on tumors can be improved.

The present invention concerns antibody-conjugate having general structure (2):AB-[(L6)-{Z—(L1)n—(L2)o—(L3)p—(L4)q-D}xx]yy   (2)wherein AB is an antibody capable of targeting Trop-2-expressing tumours and D is selected from the group consisting of taxanes, anthracyclines, camptothecins, epothilones, mytomycins, combretastatins, vinca alkaloids, maytansinoids, enediynes such as calicheamicins, duocarmycins, tubulysins, amatoxins, bleomycins, dolastatins and auristatins, pyrrolobenzodiazepine dimers, indolinobenzodiazepine dimers, radioisotopes, therapeutic proteins and peptides (or fragments thereof), kinase inhibitors, MEK inhibitors, KSP inhibitors, and analogues or prodrugs thereof. These antibody-conjugates exhibit an improved therapeutic index. The invention further concerns a process for preparing the antibody-conjugate according to the invention, a method for targeting Trop-2-expressing cells, medical uses of the antibody-conjugates according to the invention.

The invention discloses an intraoperative extracorporeal Schlemm tube positioning method and application of the intraoperative extracorporeal Schlemm tube positioning method in a glaucoma surgery, and the intraoperative extracorporeal Schlemm tube positioning method comprises the steps that a conjunctival flap with a dome as a base is manufactured, a full-thickness bulbar conjunctiva is cut off along the corneal limbus radian through a conjunctival shear, and the cut-off length is 8 + / -2 mm; performing blunt separation by clinging to the sclera surface to form a rectangular sclera area; the method comprises the following steps: manufacturing a superficial sclera flap taking limbus corneae as a substrate, forwards sectioning a sclera to a transparent cornea area, placing a mitomycin cotton piece under the sclera flap, staying for 3 minutes, and flushing; a light ring and a shadow ring are observed to be formed on the whole corneal limbus by means of irradiation of the positioning optical fiber device, and lineation marking is carried out; carrying out 1mm * 2mm deep sclera flap sectioning in the direction from 1mm behind the marking line to the limbus corneae until the limbus corneae is transparent; in the sectioning process, 0.3 mm-0. 5 mm in front of the marking line is the rear edge of the outer path Schlemm tube, the outer wall of the outer path Schlemm tube can be opened by conducting conventional fine sectioning on the outer path Schlemm tube at the position, positioning is accurate, and the surgical success rate can be improved.

The application discloses a molecular imprinting ratio type working electrode for detecting mitomycin C and a preparation method and application thereof, and belongs to the technical field of analysis and detection. The application aims to solve the problem of simple and accurate detection of the content of mitomycin C (MMC). The application adopts a solvothermal reaction to prepare cerium-nickel bimetallic organic framework material, adopts ultrasonic reaction to prepare cerium-nickel bimetallic organic framework / multi-walled carbon nanotube composite material, and adopts the cerium-nickel bimetallic organic framework / multi-walled carbon nanotube composite material and thionine as a modification material of an electrochemical sensing interface. A molecular imprinting ratio type electrochemical sensor with specific recognition response to a template molecule MMC is prepared on the surface of the modified electrode through an electrochemical polymerization method. The application is applied to the detection of the content of MMC, and has the advantages of simple operation, low cost, high sensitivity and good selectivity.

The invention discloses a molecularly imprinted ratio-type working electrode for detecting mitomycin C as well as a preparation method and application of the molecularly imprinted ratio-type working electrode, and belongs to the technical field of analysis and detection. The invention aims to solve the problem that the content of mitomycin C (MMC) can be simply, conveniently and accurately detected. According to the preparation method, a cerium-nickel bimetal organic framework material is prepared through solvothermal reaction, a cerium-nickel bimetal organic framework / multi-walled carbon nanotube composite material is prepared through ultrasonic reaction, and the cerium-nickel bimetal organic framework / multi-walled carbon nanotube composite material and thionine are used as modification materials of an electrochemical sensing interface. And preparing the molecular imprinting ratio type electrochemical sensor with specific recognition response to the template molecule MMC on the surface of the modified electrode through an electrochemical polymerization method. The method is applied to MMC content detection, and has the advantages of simple operation, low cost, high sensitivity and good selectivity.

The invention discloses an energizing method for improving the exosome secretion amount and the immunosuppression function of mesenchymal stem cells, and relates to the technical field of biomedicine, the energizing method for improving the exosome secretion amount and the immunosuppression function of the mesenchymal stem cells comprises the following steps: S1, performing multiplication culture on the mesenchymal stem cells; s2, when the fusion degree of the mesenchymal stem cells reaches 60% or above, mitomycin C is added for co-culture pretreatment; s3, performing energizing pretreatment on the mesenchymal stem cells by adopting a pretreatment culture medium added with cell factors; and S4, exosome extraction and purification. MSCs are treated through mitomycin C, so that proliferation of the MSCs is stopped at a proper fusion degree; specific cell factors are added into a culture medium to form a new pretreatment culture medium, and the MSCs are pretreated by using the pretreatment culture medium, so that the yield of the exosome is remarkably increased, and the energizing exosome with a stronger immunosuppression function is obtained.

Pharmaceutical compositions and methods for sustained release of therapeutic agents for local treatment of cancer diseases involve embedding lyophilized mitomycin C in a slowly releasing biocompatible hydrogel applied to affected tissue. The mitomycin C is lyophilized in a composition using urea as a bulking agent, and the mitomycin C and the bulking agent are present in a ratio of from about 1:7 to about 1:9 in the lyophilized pharmaceutical composition.

This invention relates to the field of nanomaterials technology, specifically to a catechol derivative ligand and its modified gold nanoparticles and their applications. The catechol derivative-modified gold nanoparticles provided by this invention can act as bioreducing agents, specifically by increasing the GSH / GSSG ratio and NADPH / NADP ratio in tumor cells. + By adjusting the ratio, reducing extracellular H2O2 content, increasing GPx content, and decreasing MDA content, a reducing stress state is formed, thus enabling it to act as a biological reducing agent. Under reducing stress, it can not only inhibit the proliferation rate of tumor cells but also activate mitomycin C, enhancing the therapeutic effect of mitomycin C on tumors.

The invention belongs to the technical field of insect cell culture, and discloses a preparation method of an Sf9 cell feeder layer, which mainly comprises the following two steps: S1, subculturing Sf9 cells: culturing the Sf9 cells in a suitable culture medium to a suitable cell confluence degree; and S2, mitomycin C treatment of the Sf9 cells: treating the subcultured Sf9 cells at specific time and temperature by using mitomycin C with specific concentration to inhibit the cell division ability of the Sf9 cells, then washing to remove the mitomycin C, and replacing a fresh culture medium. The obtained feeder layer cells can effectively inhibit self proliferation, maintain good cell activity and structural integrity, can stably survive and provide necessary support for a co-culture system, and can be used for culture of insect symbiotic bacteria and other insect cells difficult to culture; the method is easy and convenient to operate, mild in condition and good in repeatability, the prepared feeding layer is stable in effect, and a powerful tool is provided for the related research field.